{"id":704,"date":"2015-05-08T11:00:26","date_gmt":"2015-05-08T11:00:26","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=704"},"modified":"2017-08-21T11:50:24","modified_gmt":"2017-08-21T11:50:24","slug":"primary-care-corner-with-geoffrey-modest-md-prescribing-buprenorphine-in-the-emergency-room","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/05\/08\/primary-care-corner-with-geoffrey-modest-md-prescribing-buprenorphine-in-the-emergency-room\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: Prescribing buprenorphine in the emergency room"},"content":{"rendered":"<p><strong>By: Dr. Geoffrey Modest<\/strong><\/p>\n<p><span style=\"font-family: 'Calibri',sans-serif;color: black\">A recent study tested the hypothesis that it might\u00a0be useful to\u00a0initiate buprenorphine\/naloxone treatment in the emergency room\u00a0for patients with opioid dependence (see\u00a0<\/span><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\"><strong>JAMA<em><span style=\"font-family: 'Calibri',sans-serif\">.\u00a0<\/span><\/em>2015;313(16):1636-1644<\/strong>). <\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-705 alignright\" src=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/files\/2015\/05\/Emergency_room.jpg\" alt=\"Emergency_room\" width=\"357\" height=\"250\" srcset=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/files\/2015\/05\/Emergency_room.jpg 357w, https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/files\/2015\/05\/Emergency_room-300x210.jpg 300w\" sizes=\"auto, (max-width: 357px) 100vw, 357px\" \/><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">Details:<\/span><\/p>\n<p><span style=\"font-family: 'Calibri',sans-serif;color: black\">\u00a0<\/span><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;329 opioid-dependent patients coming into a large urban teaching hospital emergency department in New Haven CT\u00a0(mean age 31, 76% men, 75% white\/7% black\/16% hispanic, 41% high school grads\/41% with at least some college, 52% full time employed, 32% with private or\u00a0commercial insurance, 55% going to\u00a0private physician\u00a0or clinic for care. 34% came to ED seeking opioid treatment. 25% used only prescription opioids, 53% reported IV drug use. 88% smoked cigarettes, 55% used cocaine, 53% cannabis and 47% sedatives. alcohol use to the level of intoxication in 1\/3 of the sample. &gt;50% with prior psych treatment.<\/span><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;Randomized to referral group (screening and refer for treatment);\u00a0brief intervention (screening, brief intervention, and facilitated referral to community-based treatment service), or buprenorphine (screening, brief intervention, ED-initiated treatment with buprenorphine\/naloxone, and followed frequently, about 1x every 1-2 weeks, in\u00a0the hospital&#8217;s primary care center, then transferred at 10 weeks\u00a0to either a community program or primary care clinic or were offered a 2-week detox program)<\/span><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">Results:<\/span><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;Primary outcome (<span style=\"background: white\">enrollment in and receiving addiction treatment 30 days after randomization<\/span>): 78% of the buprenorphine group (89 of 114); 37% in the referral group (38 of 102); and 45% in the brief intervention group (50 of 111), \u00a0(p&lt;0.001)<\/span><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;Secondary outcomes<\/span><\/p>\n<p style=\"padding-left: 30px\"><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;number of days of self-reported\u00a0illicit opioid use\/week: buprenorphine: decreased from 5.4 to 0.9; referral: <span style=\"background: white\">decreased\u00a0<\/span>from 5.4 to 2.3; brief intervention: <span style=\"background: white\">decreased\u00a0<\/span>from 5.6 to 2.4. (also p&lt;0.001 for both time and intervention effects)<\/span><\/p>\n<p style=\"padding-left: 30px\"><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;<\/span><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">-rates of urine tests which were negative: no difference between groups, all in the 43-58% range<\/span><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">\u00a0<\/span><\/p>\n<p style=\"padding-left: 30px\"><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;rates of HIV risk: no difference<\/span><\/p>\n<p style=\"padding-left: 30px\"><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;use of inpatient addiction treatment services: 11% in buprenorphine, 37% in referral, and 35% in brief intervention groups (p&lt;0.001)<\/span><\/p>\n<p style=\"padding-left: 30px\"><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">&#8211;post-hoc analysis: no difference in outcome if look at subgroup who came to the ED seeking opioid treatment<\/span><\/p>\n<p><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\">A<\/span><span style=\"font-size: 11.0pt;font-family: 'Calibri',sans-serif;color: black\"> timely study, given the just-released Massachusetts report of &gt;1000 opioid-related deaths in 2014. this study has limitations in terms of its generalizability, with its short-term followup (though they\u00a0argue that this short-term followup is the one that really tests the role of the ED in identifying and getting patients into care, but it would be best to see longer term results anyway), and there needs to be lots of systems developed to be able to replicate the study (establishing a consistent screening system in the ED, training providers in buprenorphine prescribing, having sufficient and accessible referral facilities in the community, having systems to bring patients into care within a few days of the ED visit, etc). So, it would be important to replicate this study elsewhere. but I am really impressed with buprenorphine as a medication that can really give motivated\u00a0patients\u00a0back their lives. I would estimate that at least 50% of my patients do fantastically (remain illicits-free, have relationships\/jobs, can attend to their other med problems such as hepatitis C, etc). another 30+% have some problems staying completely off illicits, but are doing well\/are very functional on buprenorphine, and a small percentage either drop out or need a\u00a0more structured methadone program. And, I would agree with the study authors, giving buprenorphine in the ED setting is not fundamentally different from starting someone with concerning hypertension or hyperglycemia with appropriate drugs, and, as with buprenorphine as well, reinforces to the patient that we are taking this issue very seriously and it should have prompt treatment.<\/span><\/p>\n<p><span style=\"font-family: 'Calibri',sans-serif;color: black\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By: Dr. Geoffrey Modest A recent study tested the hypothesis that it might\u00a0be useful to\u00a0initiate buprenorphine\/naloxone treatment in the emergency room\u00a0for patients with opioid dependence (see\u00a0JAMA.\u00a02015;313(16):1636-1644). Details: \u00a0&#8211;329 opioid-dependent patients coming into a large urban teaching hospital emergency department in New Haven CT\u00a0(mean age 31, 76% men, 75% white\/7% black\/16% hispanic, 41% high school grads\/41% [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/05\/08\/primary-care-corner-with-geoffrey-modest-md-prescribing-buprenorphine-in-the-emergency-room\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-704","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=704"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/704\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}